Global Vaccine Contract Manufacturing Market Market Trends, Share, Size and Forecast Report 2024-2032

Vaccine Contract Manufacturing Market Size And Forecast

Vaccine Contract Manufacturing Market size was valued at USD 2.25 Billion in 2020 and is projected to reach USD 4.76 Billion by 2028, growing at a CAGR of 9.2% from 2021 to 2028.

The safety and the effectiveness of inoculations, the number of products developed per year is also an important factor to consider while planning the manufacturing process. This is mainly due to an increase in the number of countries demanding the introduction of vaccines. The pharmaceutical industry needs to address this rising global demand to cater to the growing population of varied age groups. The Global Vaccine Contract Manufacturing Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Vaccine Contract Manufacturing Market Definition

The vaccine is a biological preparation that offers the acquired immunity of a specific disease. There are numerous vaccines available in the market that help to treat the conditions as per patients’ needs. Owing to the stringent regulations and standards of the government, vaccine manufacturers are mandatory to follow some of the guidelines for vaccine development. Nowadays, the biopharmaceutical and pharmaceutical industries have been coming with advanced technologies in vaccine manufacturing. The vaccine contract services offer the cost-saving benefits for their clients. They also help to save time in operations & the management of a research and production facility.

Global Vaccine Contract Manufacturing Market Overview

The major factors contributing to the growth of the global Vaccine Contract Manufacturing Market include decreased time for the market, cost benefits in the infrastructure, and operational benefits. Additionally, the advancements in technology, including the introduction of the new expression systems such as GPEx and EB66 cell lines and the cell culture media platforms are some other major factors that are expected to propel the market growth. On the flip side, few large firms consider outsourcing is risky due to the loss of strategic control and limited management control.

The massive investments in facilities, equipment, and skilled labor in countries seeking to augment or localize inoculation supply are the factors expected to positively influence the adoption of contract services. Furthermore, certain low-resource countries have lack equipment and the skilled labor for production, which further compels them to form partnerships with the contract manufacturers to Vaccine Contract Manufacturing Market demand.

Though, few large firms consider outsourcing risky due to loss of strategic control and limited management control. Owing to this, the large pharma companies choose to maintain their manufacturing operations in-house. This factor is expected to hinder the global adoption of contract services throughout the forecast period.

Global Vaccine Contract Manufacturing Market: Segmentation Analysis

The Global Vaccine Contract Manufacturing Market is Segmented on the basis of Vaccine Type, Application Type, Workflow Type, And Geography.

Vaccine Contract Manufacturing Market, By Vaccine Type

• Attenuated Vaccine• Inactivated Vaccine• Subunit Vaccines• Toxoid Vaccines• DNA Vaccines

Based on Vaccine Type, the market is segmented into Attenuated Vaccine, Inactivated Vaccine, Subunit vaccines, Toxoid Vaccines, and DNA Vaccines. Attenuated vaccines accounted for the major share owing to their ability to elicit strong cellular and antibody responses. Inactivated inoculations also accounted for a significant share, as these are safer and relatively more stable than other types. The subunit segment is anticipated to witness steady growth over the forecast period owing to ongoing research for the development of recombinant subunit vaccines against the Hepatitis C virus.

Vaccine Contract Manufacturing Market, By Application Type

• Human Use• Veterinary

Based on Application Type, the market is segmented into Human Use and Veterinary. The usage and effectiveness of inoculations are not only limited to humans, but to animals as well. The human-use segment captured the largest share. Widespread vaccination coverage against a wide range of illnesses in humans has led to this segment acquiring the dominant spot in the market. Furthermore, with growth in the human population, demand for animal-based food continues to grow. Henceforth, the importance of vaccination in the meat-production industry is also expected to increase. These factors are likely to stoke the growth of the segment.

Vaccine Contract Manufacturing Market, By Workflow Type

• Upstream• Downstream

Based on Workflow Type, the market is segmented into Upstream and Downstream. Downstream processing includes product recovery and purification steps, it requires immense attention and capital. Henceforth, a high requirement for enhanced biotechnological tools, capital, and skilled personnel for recovery of the vaccine as the final product is a major factor that has boosted the growth of the segment over the past years. The upstream process is expected to arise as the fastest-growing segment in vaccine contract manufacturing.

Vaccine Contract Manufacturing Market, By Geography

• North America• Europe• Asia Pacific• Rest of the world

On the basis of Geography, the Global Vaccine Contract Manufacturing Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America accounted for the largest share in this market mainly due to the widespread manufacturing of vaccines in the region, coupled with the growing presence of a substantial number of biopharmaceutical facilities. State and other laws pertaining to the development of vaccines and other biologics in North America, particularly in the U.S. and Canada, are expected to significantly impact the progress of contract manufacturing organizations (CMOs) and contract research organizations (CROs) in the field.

The Asia Pacific market for contract manufacturing organizations and contract research organizations involved in the development of inoculations is growing at a significant pace. APAC is also expected to emerge as the fastest-growing regional market for research, development, and manufacturing of inoculations. This can be attributed to factors such as recent regulatory changes, improving infrastructure in several developing countries, and the presence of numerous potential study subjects.

Key Players

The “Global Vaccine Contract Manufacturing Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Merck KGaA, Lonza, IDT Biologika GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Cytovance Biologics, Catalent, Inc., Ajinomoto Althea, Inc., Albany Molecular Research, Inc., PRA Health Sciences, and ICON plc.

Acquisition of emerging and small players and facility expansion are among key business strategies likely to be undertaken by these companies to retain as well as enhance their share in the market over the forecast period.

Key Developments

Partnerships, Collaborations and Agreements

• June 2, 2021. Lonza and Moderna Announce Expanded Collaboration For COVID-19 Vaccine Drug Substance Manufacturing In the Netherlands, Moderna.

• April 2021. Cytovance Biologics and Akshaya Biohave Announced a Therapeutic Collaboration Agreement for the Treatment of Coronavirus and Hepatitis B Virus Infections.

Mergers and Acquisitions

• August 1, 2019. FUJIFILM Corporation announced the completion of its acquisition of Biogen (Denmark) Manufacturing ApS, a large-scale biologics manufacturing site in Hillerd near Copenhagen, Denmark (“Hillerd Manufacturing”), from Biogen.

• ICON has completed the previously announced acquisition of contract research company PRA Health Sciences for approximately $12 billion. In February 2021, the companies agreed to merge, with ICON paying $80 in cash per share and 0.4125 shares of PRA stock to PRA shareholders.

Product Launches and Product Expansions

• May 6, 2021. Lonza Announces Next-Generation Mammalian Manufacturing Facility Expansion Plans in Visp (CH) and Portsmouth (US).

• July 2020, Fujifilm Diosynth Biotechnologies announces expansion of its cell culture process development labs as well as the creation of a new bio campus as part of the expansion of its Billingham, United Kingdom site.

Report Scope

Top Trending Reports:

Research Methodology of Market Research:

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.